Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).

Journal Article (Clinical Trial;Journal Article)

The relation of cardiac troponin-I (cTnI) to clinical outcomes was examined in patients with decompensated heart failure and concomitant acute coronary syndrome enrolled into the Randomized Intravenous TeZosentan 4 (RITZ-4) study. RITZ-4 was a multicenter, randomized, double-blind, placebo-controlled trial of the endothelin receptor antagonist tezosentan in patients admitted with acute heart failure and concomitant acute coronary syndrome. One hundred ninety-two patients were enrolled in this study. Patients with baseline cTnI values were included in this analysis, and the relation between cTnI and the composite clinical primary end point of RITZ-4 was evaluated.

Full Text

Duke Authors

Cited Authors

  • Gattis, WA; O'Connor, CM; Hasselblad, V; Adams, KF; Kobrin, I; Gheorghiade, M

Published Date

  • June 1, 2004

Published In

Volume / Issue

  • 93 / 11

Start / End Page

  • 1436 - A10

PubMed ID

  • 15165935

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/j.amjcard.2004.02.051


  • eng

Conference Location

  • United States